论文部分内容阅读
目的探讨表面增强激光解吸电离飞行时间质谱(SELDI TOF MS)技术筛查乳腺癌血清特异性蛋白质的临床意义。方法应用SELDI TOF MS技术检测38例乳腺癌、33例乳腺良性疾病和43例健康对照者的血清蛋白质指纹图谱,并联合应用BioMarkerWizard3.01及BioMarkerPattern Software5.01软件分析处理数据,筛选肿瘤标志物并建立诊断模型。结果质荷比分别为M2077_07、M1827_38、M2650_51和M2060_62的4个蛋白质峰组合构建的诊断模型Ⅰ,鉴别乳腺癌和非乳腺癌的交叉验证敏感性为73.7%(28/38),特异性为73.7%(56/76)。质荷比分别为M2251_62、M3405_56、M3428_16、M4666_98和M16239_8的5个蛋白质峰组合构建的诊断模型Ⅱ,鉴别Ⅰ期乳腺癌和乳腺良性疾病的交叉验证敏感性为84.8%(28/33),特异性为55.6%(5/9)。质荷比分别为M1701_48、M3116_17、M1676_88、M5890_33和M2921_02的5个蛋白质峰组合的诊断模型Ⅲ,鉴别Ⅰ期与Ⅱ～Ⅳ期乳腺癌的交叉验证敏感性为88.9%(8/9),特异性为86.2%(25/29)。结论SELDI TOF MS技术在乳腺癌的筛查、早期诊断及临床分期判定等方面具有一定价值,值得进一步深入研究。
Objective To investigate the clinical significance of surface-enhanced laser desorption / ionization time-of-flight mass spectrometry (SELDI TOF MS) in the screening of serum-specific proteins in breast cancer. Methods Serum protein fingerprints of 38 cases of breast cancer, 33 cases of benign breast diseases and 43 healthy controls were detected by SELDI TOF MS. The data were analyzed by BioMarker Wizard 3.01 and BioMarker Patient Software 5.01 to screen tumor markers Establish a diagnostic model. RESULTS: The diagnostic model Ⅰ constructed by combination of four protein peaks with M / M ratios of M2077_07, M1827_38, M2650_51 and M2060_62 was 73.7% (28/38) for differential breast cancer and 73.7% for non-breast cancer % (56/76). The diagnostic model Ⅱ constructed by combination of five protein peaks with mass-to-charge ratios of M2251_62, M3405_56, M3428_16, M4666_98 and M16239_8, respectively, showed that the sensitivity of cross-validation in stage Ⅰ breast cancer and benign breast disease was 84.8% (28/33) Sex was 55.6% (5/9). The mass-to-charge ratios of M1701_48, M3116_17, M1676_88, M5890_33 and M2921_02 were respectively8.8% (8/9) for differential diagnosis of stageⅠandⅡ ~ Ⅳ breast cancer, Sex was 86.2% (25/29). Conclusion SELDI TOF MS has some value in the screening, early diagnosis and clinical staging of breast cancer, which deserves further study.